Datasets:

nzindoc

/

dataset-multiple-myeloma

like 0

The effect of concurrent health conditions on the median PFS for Carfilzomib+Dexamethasone (Kd) ;.

The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Carfilzomib+Dexamethasone (Kd) ;. ### Response: The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)}

Median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd)?

The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd)? ### Response: The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)}

Comparison of the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd) with other treatment regimens.

The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Comparison of the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd) with other treatment regimens. ### Response: The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)}

The impact of patient characteristics on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd).

The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of patient characteristics on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd). ### Response: The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)}

The role of genetic factors in the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd).

The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of genetic factors in the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd). ### Response: The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)}

The influence of previous treatments on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd).

The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of previous treatments on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd). ### Response: The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)}

The effect of dosage and administration frequency on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd).

The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of dosage and administration frequency on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd). ### Response: The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)}

The correlation between the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd) and overall survival rates.

The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The correlation between the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd) and overall survival rates. ### Response: The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)}

The impact of side effects and adverse reactions on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd).

The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The impact of side effects and adverse reactions on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd). ### Response: The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)}

The role of supportive care in improving the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd).

The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The role of supportive care in improving the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd). ### Response: The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)}

The influence of disease stage at the start of treatment on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd).

The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The influence of disease stage at the start of treatment on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd). ### Response: The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)}

The effect of concurrent health conditions on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd).

The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)}

Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The effect of concurrent health conditions on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd). ### Response: The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) ^{[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)}